Cargando…

Addressing blood-brain-tumor-barrier heterogeneity in pediatric brain tumors with innovative preclinical models

Brain tumors represent the leading cause of disease-related mortality and morbidity in children, with effective treatments urgently required. One factor limiting the effectiveness of systemic therapy is the blood-brain-barrier (BBB), which limits the brain penetration of many anticancer drugs. BBB i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morris, Elysse K., Daignault-Mill, Sheena, Stehbens, Samantha J., Genovesi, Laura A., Lagendijk, Anne K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909546/ https://www.ncbi.nlm.nih.gov/pubmed/36776301 http://dx.doi.org/10.3389/fonc.2023.1101522

Ejemplares similares

MDB-42. UNCOVERING DYNAMIC CHANGES IN MEDULLOBLASTOMA ASSOCIATED VASCULATURE IN ZEBRAFISH
por: Morris, Elysse, et al.
Publicado: (2023)

Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity
por: Brighi, Caterina, et al.
Publicado: (2020)

Preclinical Models of Pediatric Brain Tumors—Forging Ahead
por: Dobson, Tara H.W., et al.
Publicado: (2018)

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
por: Griffith, Jessica I., et al.
Publicado: (2020)

Innovation in Brain Tumor Treatment: A Nurse Perspective
por: Reddelle, Alexandria K
Publicado: (2021)

Brain Microenvironment Heterogeneity: Potential Value for Brain Tumors
por: Álvaro-Espinosa, Laura, et al.
Publicado: (2021)

ANK1 is up-regulated in laser captured microglia in Alzheimer’s brain; the importance of addressing cellular heterogeneity
por: Mastroeni, Diego, et al.
Publicado: (2017)

Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
por: Morfouace, Marie, et al.
Publicado: (2015)

BIOL-11. PRECLINICAL MODELLING OF PEDIATRIC BRAIN TUMORS USING ORGANOID TECHNOLOGY
por: Roosen, Mieke, et al.
Publicado: (2023)

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease
por: Breckwoldt, Michael O., et al.
Publicado: (2019)

IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
por: Mishra, Deepak, et al.
Publicado: (2023)

Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors
por: Belykh, Evgenii, et al.
Publicado: (2020)

Correction: ANK1 is up-regulated in laser captured microglia in Alzheimer's brain; the importance of addressing cellular heterogeneity
por: Mastroeni, Diego, et al.
Publicado: (2018)

Breaching the Blood–Brain Tumor Barrier for Tumor Therapy
por: Marcucci, Fabrizio, et al.
Publicado: (2021)

Disruption of Vascular Barriers in Tumors and in the Brain
por: McDannold, Nathan
Publicado: (2015)

Addressing intra-tumoral heterogeneity and therapy resistance
por: Rybinski, Brad, et al.
Publicado: (2016)

Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance
por: Mo, Francesca, et al.
Publicado: (2021)

Focused ultrasound-induced blood–brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study
por: Chen, Pin-Yuan, et al.
Publicado: (2015)

MODL-30. Children’s Brain Tumor Network preclinical tumor models development and sharing platform: collaborative model empowering pediatric brain tumor discovery and global research.
por: Koptyra, Mateusz, et al.
Publicado: (2022)

BIOL-22. CHILDREN’S BRAIN TUMOR NETWORK PRECLINICAL TUMOR MODELS DEVELOPMENT AND SHARING PLATFORM: COLLABORATIVE MODEL EMPOWERING PEDIATRIC BRAIN TUMOR DISCOVERY AND GLOBAL RESEARCH
por: Hollawell, Madison, et al.
Publicado: (2023)

The role of digital transformation in addressing health inequalities in coastal communities: barriers and enablers
por: Asthana, Sheena, et al.
Publicado: (2023)

Biomarkers of Pediatric Brain Tumors
por: Russell, Mark D., et al.
Publicado: (2013)

Addressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
por: Sharma, Chanchal, et al.
Publicado: (2022)

Addressing cellular heterogeneity in tumor and circulation for refined prognostication
por: Lim, Su Bin, et al.
Publicado: (2019)

Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
por: Bhowmik, Arijit, et al.
Publicado: (2015)

An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors
por: Yakisich, Juan Sebastian
Publicado: (2012)

Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α
por: Corti, Angelo, et al.
Publicado: (2022)

Tumor heterogeneity: preclinical models, emerging technologies, and future applications
por: Proietto, Marco, et al.
Publicado: (2023)

Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors
por: Calabrese, Giovanna, et al.
Publicado: (2021)

Remodeling the blood–brain barrier microenvironment by natural products for brain tumor therapy
por: Zhao, Xiao, et al.
Publicado: (2017)

Editorial: The blood-brain barrier in brain tumors: molecular mechanisms and therapeutic strategies
por: Zhang, Lei, et al.
Publicado: (2023)

Emerging Insights into Barriers to Effective Brain Tumor Therapeutics
por: Woodworth, Graeme F., et al.
Publicado: (2014)

Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model
por: Hu, Jinwei, et al.
Publicado: (2007)

Editorial: Forces in biology - Cell and developmental mechanobiology and its implications in disease - Volume II
por: Wu, Selwin K., et al.
Publicado: (2022)

Circadian rhythm impacts preclinical FDG-PET quantification in the brain, but not in xenograft tumors
por: Krueger, Marcel A., et al.
Publicado: (2020)

Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin
por: Seliger, Corinna, et al.
Publicado: (2022)

Incremental Learning for Heterogeneous Structure Segmentation in Brain Tumor MRI
por: Liu, Xiaofeng, et al.
Publicado: (2023)

GEN-1 ORIGINALLY DEVELOPED TUMOR SAMPLER TO REVEAL INTRATUMORAL HETEROGENEITY IN BRAIN TUMORS
por: Otani, Ryohei, et al.
Publicado: (2022)

Immunotherapy for Pediatric Brain Tumors
por: Sayour, Elias J., et al.
Publicado: (2017)

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
por: Durant, Stephen T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j8bfetd9o1n2hqh9ks4kqlbrs7